Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 11/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | CTSV | O60911 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22886648 | 0.86 | CAPN1 (0.48) | CAPN1CTSS | |
| SCHEMBL20028606 | 0.82 | PYGL (0.43) | DCAF1PYGLCCR1CNR1CNR2 | |
| SCHEMBL22886551 | 0.81 | PYGL (0.41) | DCAF1PYGLCNR1CNR2CARM1 | |
| SCHEMBL22885920 | 0.79 | PYGL (0.40) | DCAF1PYGLCCR1CNR1CNR2 | |
| SCHEMBL22886791 | 0.79 | DCAF1 (0.39) | DCAF1PYGLCCR1CNR1CNR2 | |
| SCHEMBL22886565 | 0.78 | DCAF1 (0.37) | DCAF1PYGLCCR1CNR1CNR2 | |
| SCHEMBL20027617 | 0.78 | PYGL (0.43) | DCAF1PYGLCCR1CNR1CNR2 | |
| SCHEMBL22886578 | 0.78 | IDO1 (0.44) | DCAF1PYGLCCR1CNR1CNR2 | |
| SCHEMBL22897214 | 0.77 | DCAF1 (0.51) | DCAF1PYGLCNR1CNR2CTSV | |
| SCHEMBL20027914 | 0.76 | DCAF1 (0.48) | DCAF1PYGLCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | DCAF1 2355/4885PYGL 719/4885CCR1 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.